AI is taking drug discovery by storm

Artificial intelligence (AI) and machine learning (ML) technologies are redefining the way biopharma companies discover and develop drugs.

It’s not a passing phase, either. Half of the 50 biggest pharmaceutical companies have entered into partnerships or licensing agreements with AI companies in recent years. It’s clear that pharma companies are embracing AI in droves, and if you’re in the life sciences industry, you should too.

The reasons why are simple: AI has the potential to revolutionize the drug discovery and development process, promising improved efficiency, accuracy, and speed. And according to Forbes, AI is slashing drug discovery costs for pharmaceutical companies by a whopping 70%.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma’s Cathal Friel assumes role of Executive Chairman

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced a change of Board role and the Remuneration Committee’s approval of

What will cancer therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a

Reducing cancer immunotherapy-induced CRS

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.